title: Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate.
abstract: Patients with hemophilia A or von Willebrand's disease who are treated with concentrated preparations of human factor VIII made from unscreened pooled plasma are at substantial risk of contracting human immunodeficiency virus (HIV) infection. The purpose of this study was to investigate whether by treating such patients with a pasteurized factor VIII concentrate that had been heated in aqueous solution at 60 degrees C for 10 hours, HIV infection could be avoided. Eleven hemophilia centers in the Federal Republic of Germany and two in Austria identified 155 eligible patients who had been treated exclusively with pasteurized factor VIII concentrate and had not received any other blood products. Between February 1979 and December 1986 they received a total of 15,916,260 IU of pasteurized factor VIII. The United States was the source of 80 percent of the plasma from which the concentrate was made. By September 1988, these 155 patients had been screened for antibody to HIV type 1 (anti-HIV-1) with a total of 657 tests; all were negative. Sixty-seven patients were also tested once for antibody to HIV type 2 (anti-HIV-2); all these tests were negative as well. It appears that pasteurization effectively inactivates HIV, even in plasma that is likely to be highly contaminated with the virus.
authors.affiliation: Rehabilitation Hospital, Frankfurt am Main, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Schimpf
authors.forename: H H
authors.initials: HH
authors.lastname: Brackmann
authors.forename: W
authors.initials: W
authors.lastname: Kreuz
authors.forename: B
authors.initials: B
authors.lastname: Kraus
authors.forename: F
authors.initials: F
authors.lastname: Haschke
authors.forename: W
authors.initials: W
authors.lastname: Schramm
authors.forename: J
authors.initials: J
authors.lastname: Moesseler
authors.forename: G
authors.initials: G
authors.lastname: Auerswald
authors.forename: A H
authors.initials: AH
authors.lastname: Sutor
authors.forename: K
authors.initials: K
authors.lastname: Koehler
mesh_terms: D001317:Austria / Q000453:epidemiology; D005169:Factor VIII / Q000627:therapeutic use*; D005860:Germany, West / Q000453:epidemiology; D015658:HIV Infections / Q000517:prevention & control*; D006679:HIV Seropositivity / Q000453:epidemiology*; D015497:HIV-1 / Q000276:immunology*; D015498:HIV-2 / Q000276:immunology*; D006467:Hemophilia A / Q000628:therapy*; D006358:Hot Temperature; D006801:Humans; D014842:von Willebrand Diseases / Q000628:therapy*
chemical_list: D005169:Factor VIII